Venomics AI Private Limited has raised $2.7 million in pre-seed financing co-led by Speciale Invest and South Park Commons, with participation from Operators Studio. Ikigai Law, GameChanger Law Advisors and Khaitan & Co advised the company and the two lead investors on the transaction.
Senior Partner Samheeta Rao led GameChanger Law Advisors’ transaction team advising Speciale Invest. Ikigai Law represented Venomics AI, while Khaitan & Co advised South Park Commons, according to the transaction report published by Bar & Bench on November 7.
The Bengaluru-based biotechnology company, spun out of the Indian Institute of Science (IISc), combines venom biology, artificial intelligence and experimental screening to identify molecules that could become therapeutic candidates. The capital will support its molecular database, research infrastructure and multidisciplinary team.
The financing brings together an early-stage drug-discovery proposition and a legal context extending beyond investment documentation. An investor has expressly identified biodiversity regulation as relevant to the business, although the disclosed material does not establish any company-specific approval, change in control or regulatory determination.
Key Highlights
First institutional round: Venomics AI raised $2.7 million from Speciale Invest, South Park Commons and Operators Studio.
Legal advisers: Ikigai Law advised the company, GameChanger Law Advisors advised Speciale Invest, and Khaitan & Co advised South Park Commons.
Transaction leadership: Senior Partner Samheeta Rao led GameChanger Law Advisors’ team for Speciale Invest.
Research deployment: Proceeds will expand the Venom Atlas database, strengthen AI and laboratory screening, and support recruitment and molecule validation.
Regulatory distinction: Biodiversity compliance features in Speciale Invest’s thesis, but no company-specific approval or investment-related permission is disclosed.
Venomics AI raises $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons
The $2.7 million raise is described by Business Standard as Venomics AI’s first institutional funding round. Speciale Invest and South Park Commons co-led the financing, with Operators Studio participating. The reports do not disclose the investors’ respective contributions, the company’s valuation or the ownership acquired.
The chronology requires a distinction between the company’s own funding milestone and subsequent press coverage. Venomics AI’s news page dates the financing to April 10, 2026, identifying the same investor syndicate. That entry does not, by itself, establish the legal closing date or explain the interval before the November reports.
South Park Commons published its investment thesis on November 4. Business coverage followed on November 5: ETEntrepreneur published at 11:46 a.m. IST, while Business Standard first published at 3:57 p.m. IST and updated its report at 4:49 p.m. IST. The legal-adviser report appeared on November 7, displaying a publication time of 6:24 a.m.
These dates establish a company-stated April milestone and a November reporting sequence, rather than a single verified closing event. The immediate disclosed outcome is the financing itself, with deployment directed towards building the discovery platform rather than launching an approved medicine.
Ikigai Law, GameChanger Law Advisors and Khaitan & Co advise on the financing
Ikigai Law advised Venomics AI on the fundraise. GameChanger Law Advisors advised Speciale Invest, while Khaitan & Co advised South Park Commons. The mandates distinguish company-side representation from the separate representation of each lead investor.
The disclosed report does not identify individual transaction leaders at Ikigai Law or Khaitan & Co. Nor does it name an adviser for Operators Studio. The professional credits therefore cannot be extended to additional lawyers, firms or participants beyond those expressly reported.
In a private financing, company and investor advisers ordinarily address different interests within the same transaction. Matters such as investment conditions, governance, information rights and the allocation of contractual risk can be material to that process. Here, however, the reports do not disclose the negotiated rights or establish which particular issues arose.
The investment instrument, transaction documents, board arrangements, legal fees and closing mechanics have not been identified. No particular Companies Act procedure, foreign-investment route, RBI filing or SEBI requirement can consequently be reported as a confirmed feature of this financing. The announcement establishes the mandates and amount raised, not the underlying legal architecture.
Samheeta Rao leads GameChanger Law Advisors’ team for investor Speciale Invest
Samheeta Rao, Senior Partner at GameChanger Law Advisors, led the firm’s transaction team for Speciale Invest. That is the individual leadership credit disclosed in the legal report. It identifies her mandate as investor-side representation, not representation of Venomics AI or South Park Commons.
The distinction matters in a financing involving multiple participants and separate advisers. A lawyer’s leadership of one investor’s transaction team does not establish a mandate for the company or the syndicate as a whole. No additional GameChanger Law Advisors team members are named in the reviewed material.
Speciale Invest’s published rationale places emphasis on the founders’ complementary capabilities. Kartik Sunagar brings venom research expertise, while co-founder and chief technology officer Vinay Prabhu contributes machine-learning experience and holds a Carnegie Mellon University PhD. Arjun Rao, general partner at Speciale Invest, said:
“Vinay brings the AI depth to accelerate this bio-discovery.”
Those comments explain the investor’s commercial assessment of the team. They do not disclose the scope of legal diligence, any contractual protection or any opinion delivered by counsel. The confirmed legal credit remains that Rao led GameChanger Law Advisors’ team advising Speciale Invest on the fundraise.
Venom Atlas combines biological data, AI prioritisation and laboratory screening
Venomics AI’s discovery model begins with venom biology and molecular sequencing. These feed into the Venom Atlas, a growing molecular database intended to connect biological information with experimentally assessed activity. AI is then used to prioritise molecules for further investigation.
The computational stage is followed by laboratory functional screening. Experimental results feed back into subsequent predictions and molecular design, creating an iterative process rather than a purely software-led search. The distinction is important: selecting a promising molecule computationally is not equivalent to demonstrating its therapeutic effectiveness.
Sunagar, the company’s founder and director and an IISc professor, described the biological opportunity in these terms:
“Animal venoms represent one of nature’s richest yet least explored sources of potential medicines”.
Sunagar contributes expertise in venom evolution and antivenom development, alongside Prabhu’s computational capabilities. Their proposition is to combine those disciplines so that laboratory resources can be focused on more promising candidates. The reported statements describe a discovery strategy and its intended potential, not evidence that Venomics AI has produced an approved drug or established clinical benefit.
Funding to expand the database, strengthen research capabilities and build a multidisciplinary team
The proceeds are intended to expand the Venom Atlas, enhance the AI platform and strengthen laboratory screening. They will also support a multidisciplinary team spanning venom biology, computational science and drug discovery, together with the validation and optimisation of promising molecules.
These priorities cover distinct parts of the research process. Database expansion increases the material available for analysis; computational development supports prioritisation; and laboratory screening tests whether predicted activity is observed experimentally. Validation and optimisation then concern the further assessment and refinement of selected molecules, rather than their automatic progression into medicines.
The company’s chronology places its conceptualisation in January 2026, when Sunagar and Prabhu met in India after 15 years. Venomics AI says it entered the ARTPARK Venture Incubation Programme at the AI & Robotics Technology Park, I-Hub at IISc, on July 13.
It also records being among the top five finalists for the 2026 Indo-Boston Biotech Bridge Award in July, an initiative involving Nucleate India and the Association of Biotechnology Led Enterprises, powered by LabCentral. Its NVIDIA Inception acceptance announcement is dated August 20. These are company-reported development milestones, not substitutes for product validation; no spending allocation, recruitment target or research-completion timetable is disclosed.
Investors point to proprietary experimental data and antimicrobial resistance as the initial focus
Speciale Invest’s thesis, authored by Sunil Cavale, identifies differentiated experimental data as a central investment consideration. It describes the Atlas as a proprietary map linking venom peptides to measured activity. The argument is that biological information generated through fieldwork and laboratory effort may distinguish the business more meaningfully than access to AI models alone.
South Park Commons similarly stresses the connection between computational prioritisation and experimental validation. Writing on its official website, Prateek Mehta characterised the opportunity as:
“The oldest drug discovery lab on Earth, finally searchable.”
Mehta identifies antimicrobial resistance as the company’s initial target. His thesis also acknowledges that a model’s prediction remains a hypothesis until laboratory testing supports it, and that turning discoveries into drugs remains difficult. The proposed advantage is therefore a more focused discovery process, not certainty of a successful therapeutic outcome.
Sunagar’s reported comments place the investment within an ambition to build an India-based discovery platform drawing on domestic biodiversity and scientific talent for global therapeutic development. That ambition, like the investors’ assessments of the database and founding team, remains forward-looking. The disclosed reports do not identify an approved medicine, a clinical outcome or a demonstrated commercial return.
Biodiversity compliance is part of the investment thesis, but no company-specific approval is disclosed
Speciale Invest’s thesis expressly raises the amended Biological Diversity Act in discussing access to Indian biological resources. It refers to prior approval for foreign-controlled entities accessing such resources, including isolated peptides, and treats permissions and fieldwork as relevant to building the company’s data resource.
This introduces a regulatory dimension distinct from the financing documentation. Access to biological material and the subsequent research use of that material cannot simply be equated with the receipt of investment. Equally, a reference to the governing legislation does not establish that a particular permission applies to, or has been obtained by, Venomics AI.
The published material supplies no company-specific approval number, compliance determination or approved biological-resource access arrangement. It also does not establish that this fundraise changes the company’s control status. Any conclusion about a resulting approval obligation would therefore go beyond the disclosed facts.
The next steps identified in the announcement remain operational: expanding the database, strengthening AI and laboratory capabilities, building the team, and validating and optimising candidate molecules. No regulatory direction or adjudicatory outcome forms part of the reported development.
Legal representation: Ikigai Law advised Venomics AI; GameChanger Law Advisors advised Speciale Invest, with Senior Partner Samheeta Rao leading its transaction team; and Khaitan & Co advised South Park Commons. Counsel for Operators Studio was not identified in the disclosed report.
Sources